1h Free Analyst Time
The Human Insulin Drugs Market size was estimated at USD 57.26 billion in 2023, USD 62.02 billion in 2024, and is expected to grow at a CAGR of 8.78% to reach USD 103.22 billion by 2030. Speak directly to the analyst to clarify any post sales queries you may have.
Human insulin drugs contain the hormone insulin, produced naturally in the body. They are used to treat people with diabetes, a medical condition in which the body cannot produce enough insulin or properly regulate blood sugar levels. Human insulin drugs help regulate blood sugar levels by providing additional insulin to the body, either directly or indirectly. Human insulin is created by recombinant DNA technology, similar to endogenously produced insulin. Typically prescribed for managing hyperglycemia caused by Type 1 and Type 2 Diabetes, insulin is a peptide hormone made by beta cells of the pancreas that stimulates glucose metabolism. Several types of human insulin drugs are available, including rapid-acting insulins, short-acting insulins, intermediate-acting insulins, and long-acting insulins. Each type of human insulin drug works differently and has distinct benefits and drawbacks. The rising prevalence of diabetic patients and the growing burden of obesity and the senior population have enhanced the usage of human insulin drugs. Technological advancements in drug delivery systems also pave the way for the human insulin drugs market. On the other hand, associated high costs, adverse health impacts, and stringent regulatory approvals may hinder the adoption rate of human insulin. Nevertheless, surging investments for ongoing research & development activities and notable changes in the regulatory landscape may create lucrative scope for the human insulin drugs market.
Regional Insights
The Americas region has observed rapid growth in the human insulin drugs market owing to the presence of potential players, ongoing research and development activities, and promising government measures. Companies such as Eli Lilly, Novo Nordisk, and Sanofi-Aventis have succeeded here due to their long-standing relationships with healthcare providers nationwide. In addition, there is an increasing demand for generic versions of these medications in the United States due to their lower cost. The Europe, Middle East, and Africa (EMEA) region is the significant consumer of human insulin drugs due to the high prevalence of diabetic patients and the geriatric population in the region. Moreover, European countries have high levels of affluence and access to quality healthcare services. Therefore, the need for these types of drugs is very high. The Asia-Pacific (APAC) region has experienced rapid growth regarding human insulin drugs in recent years. As several countries in the region are investing heavily in healthcare infrastructure and services, the demand for human insulin drugs has grown significantly in recent years. Moreover, government initiatives and programs to manage diabetes have encouraged the adoption of human insulin drugs in the APAC region.FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Human Insulin Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Human Insulin Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.Key Company Profiles
The report delves into recent significant developments in the Human Insulin Drugs Market, highlighting leading vendors and their innovative profiles. These include Albireo Pharma, Inc. by Ipsen, B. Braun Melsungen AG, Biocon Limited, Bristol-Myers Squibb Company, Cadila Pharmaceuticals Limited, Eli Lilly and Company, Eris Lifesciences Ltd., Gan & Lee Pharmaceuticals Co., Ltd., Glenmark Pharmaceuticals Ltd., Gulf Pharmaceutical Industries, Innova Life Sciences Private Limited, Lupin Limited, MannKind Corporation, Merck KGaA, Novo Nordisk A/S, Pfizer Inc., Sanofi S.A., Shreya Life Sciences Pvt Ltd., Tonghua Dongbao Pharmaceutical Co., Ltd., Torrent Pharmaceuticals Ltd., Wockhardt Limited, and Zhuhai United Laboratories Co., Ltd.Market Segmentation & Coverage
This research report categorizes the Human Insulin Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:- Insulin Type
- Basal or Long-Acting Insulins
- Biosimilar Insulins
- Intermediate-Acting Insulin
- Mixed Insulins
- Rapid-Acting Insulin
- Short-Acting Insulin
- Delivery Devices
- Insulin Pens
- Insulin Pumps
- Insulin Syringes
- Application
- Gestational Diabetes
- Type 1 Diabetes
- Type 2 Diabetes
- Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
The report offers valuable insights on the following aspects:
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
- What is the market size and forecast of the Human Insulin Drugs Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the Human Insulin Drugs Market?
- What are the technology trends and regulatory frameworks in the Human Insulin Drugs Market?
- What is the market share of the leading vendors in the Human Insulin Drugs Market?
- Which modes and strategic moves are suitable for entering the Human Insulin Drugs Market?
Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report
Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.
With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.
This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.
Table of Contents
1. Preface
2. Research Methodology
4. Market Overview
5. Market Insights
6. Human Insulin Drugs Market, by Insulin Type
7. Human Insulin Drugs Market, by Delivery Devices
8. Human Insulin Drugs Market, by Application
9. Human Insulin Drugs Market, by Distribution Channel
10. Americas Human Insulin Drugs Market
11. Asia-Pacific Human Insulin Drugs Market
12. Europe, Middle East & Africa Human Insulin Drugs Market
13. Competitive Landscape
14. Competitive Portfolio
15. Appendix
List of Figures
List of Tables
Companies Mentioned
- Albireo Pharma, Inc. by Ipsen
- B. Braun Melsungen AG
- Biocon Limited
- Bristol-Myers Squibb Company
- Cadila Pharmaceuticals Limited
- Eli Lilly and Company
- Eris Lifesciences Ltd.
- Gan & Lee Pharmaceuticals Co., Ltd.
- Glenmark Pharmaceuticals Ltd.
- Gulf Pharmaceutical Industries
- Innova Life Sciences Private Limited
- Lupin Limited
- MannKind Corporation
- Merck KGaA
- Novo Nordisk A/S
- Pfizer Inc.
- Sanofi S.A.
- Shreya Life Sciences Pvt Ltd.
- Tonghua Dongbao Pharmaceutical Co., Ltd.
- Torrent Pharmaceuticals Ltd.
- Wockhardt Limited
- Zhuhai United Laboratories Co., Ltd.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 192 |
| Published | March 2024 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 62.02 Billion |
| Forecasted Market Value ( USD | $ 103.22 Billion |
| Compound Annual Growth Rate | 8.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 22 |
